{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T05:25:08Z","timestamp":1755926708938},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,4]]},"DOI":"10.7759\/cureus.29922","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T02:12:52Z","timestamp":1664935972000},"source":"Crossref","is-referenced-by-count":2,"title":["Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma"],"prefix":"10.7759","author":[{"given":"Sethi","family":"Ashish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin R","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purva","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses","family":"Raj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier M","year":"2021","unstructured":"Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol. 2021, 12:217-237. 10.5306\/wjco.v12.i4.217","journal-title":"World J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.07.025","article-title":"Genetic alterations defining NSCLC subtypes and their therapeutic implications","volume":"82","author":"Pikor LA","year":"2013","unstructured":"Pikor LA, Ramnarine VR, Lam S, Lam WL. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013, 82:179-189. 10.1016\/j.lungcan.2013.07.025","journal-title":"Lung Cancer"},{"key":"ref3","article-title":"Effect of ALK-inhibitors in the treatment of non-small cell lung cancer: a systematic review and\r\nmeta-analysis","volume":"21","author":"Li G","year":"2017","unstructured":"Li G, Dai WR, Shao FC. Effect of ALK-inhibitors in the treatment of non-small cell lung cancer: a systematic review and\r\nmeta-analysis. Eur Rev Med Pharmacol\r\n. 2017, 21:3496-3503.","journal-title":"Eur Rev Med Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.653","article-title":"Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer","volume":"101","author":"Dagogo-Jack I","year":"2017","unstructured":"Dagogo-Jack I, Shaw AT, Riely GJ. Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer. Clin Pharmacol Ther. 2017, 101:625-633. 10.1002\/cpt.653","journal-title":"Clin Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters S","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, et al.. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017, 377:829-838. 10.1056\/NEJMoa1704795","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy405","article-title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study","volume":"29","author":"Gadgeel S","year":"2018","unstructured":"Gadgeel S, Peters S, Mok T, et al.. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018, 29:2214-2222. 10.1093\/annonc\/mdy405","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1108514","article-title":"EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1\u03b1 and STAT3","volume":"5","author":"Koh J","year":"2016","unstructured":"Koh J, Jang JY, Keam B, et al.. EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1\u03b1 and STAT3. Oncoimmunology. 2016, 5:e1108514. 10.1080\/2162402X.2015.1108514","journal-title":"Oncoimmunology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.02.022","article-title":"Phase 1\/2 study of the safety and tolerability of\u00a0nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation - positive advanced non-small cell\u00a0lung cancer (CheckMate 370)","volume":"13","author":"Spigel DR","year":"2018","unstructured":"Spigel DR, Reynolds C, Waterhouse D, et al.. Phase 1\/2 study of the safety and tolerability of\u00a0nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation - positive advanced non-small cell\u00a0lung cancer (CheckMate 370). J Thorac Oncol. 2018, 13:682-688. 10.1016\/j.jtho.2018.02.022","journal-title":"J Thorac Oncol"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051184","article-title":"Review of therapeutic strategies for anaplastic lymphoma kinase-rearranged non-small cell lung cancer","volume":"14","author":"Fukui T","year":"2022","unstructured":"Fukui T, Tachihara M, Nagano T, Kobayashi K. Review of therapeutic strategies for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Cancers (Basel). 2022, 14:1184.","journal-title":"Cancers (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01589","article-title":"Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer","volume":"40","author":"Chaft JE","year":"2022","unstructured":"Chaft JE, Shyr Y, Sepesi B, Forde PM. Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer. J Clin Oncol. 2022, 40:546-555. 10.1200\/JCO.21.01589","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2984","article-title":"Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants","volume":"9","author":"Xu H","year":"2020","unstructured":"Xu H, Zhang Q, Liang L, et al.. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants. Cancer Med. 2020, 9:3328-3336. 10.1002\/cam4.2984","journal-title":"Cancer Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu YL","year":"2020","unstructured":"Wu YL, Tsuboi M, He J, et al.. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020, 383:1711-1723. 10.1056\/NEJMoa2027071","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/110260-anaplastic-lymphoma-kinase-alk-mutation-targeting-treatment-with-alectinib-in-lung-adenocarcinoma-and-primary-cutaneous-marginal-zone-b-cell-lymphoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:50Z","timestamp":1707507650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/110260-anaplastic-lymphoma-kinase-alk-mutation-targeting-treatment-with-alectinib-in-lung-adenocarcinoma-and-primary-cutaneous-marginal-zone-b-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.29922","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,4]]}}}